These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 32519164)

  • 1. Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19.
    Bautista-Vargas M; Bonilla-Abadía F; Cañas CA
    J Thromb Thrombolysis; 2020 Oct; 50(3):479-483. PubMed ID: 32519164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombotic complications of COVID-19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endosomal NADPH oxidase.
    DiNicolantonio JJ; McCarty M
    Open Heart; 2020 Jun; 7(1):. PubMed ID: 32532805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad.
    Ahmed S; Zimba O; Gasparyan AY
    Clin Rheumatol; 2020 Sep; 39(9):2529-2543. PubMed ID: 32654082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19.
    Braga CL; Silva-Aguiar RP; Battaglini D; Peruchetti DB; Robba C; Pelosi P; Rocco PRM; Caruso-Neves C; Silva PL
    Pharmacol Res Perspect; 2020 Aug; 8(4):e00623. PubMed ID: 32658389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the COVID-19 pandemic on therapeutic choices in thrombosis-hemostasis.
    Hermans C; Lambert C
    J Thromb Haemost; 2020 Jul; 18(7):1794-1795. PubMed ID: 32294321
    [No Abstract]   [Full Text] [Related]  

  • 6. Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients.
    Zhang Y; Cao W; Jiang W; Xiao M; Li Y; Tang N; Liu Z; Yan X; Zhao Y; Li T; Zhu T
    J Thromb Thrombolysis; 2020 Oct; 50(3):580-586. PubMed ID: 32648093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
    Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N
    Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral Coagulopathy in Patients With COVID-19: Treatment and Care.
    Kipshidze N; Dangas G; White CJ; Kipshidze N; Siddiqui F; Lattimer CR; Carter CA; Fareed J
    Clin Appl Thromb Hemost; 2020; 26():1076029620936776. PubMed ID: 32687449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV.
    Lubbe L; Cozier GE; Oosthuizen D; Acharya KR; Sturrock ED
    Clin Sci (Lond); 2020 Nov; 134(21):2851-2871. PubMed ID: 33146371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long lasting hypercoagulability after subclinical COVID-19.
    Ferroli P; Villa C; Ciuffi A; Gubertini G; Broggi M
    J Thromb Thrombolysis; 2020 Nov; 50(4):822-824. PubMed ID: 32757154
    [No Abstract]   [Full Text] [Related]  

  • 11. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.
    Whyte CS; Morrow GB; Mitchell JL; Chowdary P; Mutch NJ
    J Thromb Haemost; 2020 Jul; 18(7):1548-1555. PubMed ID: 32329246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H
    Yang G
    Am J Physiol Cell Physiol; 2020 Aug; 319(2):C244-C249. PubMed ID: 32515982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights.
    Divani AA; Andalib S; Di Napoli M; Lattanzi S; Hussain MS; Biller J; McCullough LD; Azarpazhooh MR; Seletska A; Mayer SA; Torbey M
    J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104941. PubMed ID: 32689643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemorrhagic stroke and anticoagulation in COVID-19.
    Dogra S; Jain R; Cao M; Bilaloglu S; Zagzag D; Hochman S; Lewis A; Melmed K; Hochman K; Horwitz L; Galetta S; Berger J
    J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104984. PubMed ID: 32689588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep venous thrombosis in a non-critically ill patient with novel COVID-19 infection.
    Nauka PC; Oran E; Chekuri S
    Thromb Res; 2020 Aug; 192():27-28. PubMed ID: 32419710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can beta-adrenergic blockers be used in the treatment of COVID-19?
    Vasanthakumar N
    Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480
    [No Abstract]   [Full Text] [Related]  

  • 17. COVID-19 and relative angiotensin-converting enzyme 2 deficiency: role in disease severity and therapeutic response.
    Ryan PM; Caplice N
    Open Heart; 2020 Jun; 7(1):. PubMed ID: 32532804
    [No Abstract]   [Full Text] [Related]  

  • 18. COVID-19 and the nervous system.
    Berger JR
    J Neurovirol; 2020 Apr; 26(2):143-148. PubMed ID: 32447630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 update: Covid-19-associated coagulopathy.
    Becker RC
    J Thromb Thrombolysis; 2020 Jul; 50(1):54-67. PubMed ID: 32415579
    [No Abstract]   [Full Text] [Related]  

  • 20. ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery.
    Lores E; Wysocki J; Batlle D
    Clin Sci (Lond); 2020 Nov; 134(21):2791-2805. PubMed ID: 33135725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.